Lange, T., & Müller, M. C. (2013). The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica, the hematology journal, 98(5), .
Chicago-Zitierstil (17. Ausg.)Lange, Thoralf, und Martin Christian Müller. "The Quantitative Level of T315I Mutated BCR-ABL Predicts for Major Molecular Response to Second-line Nilotinib or Dasatinib Treatment in Patients with Chronic Myeloid Leukemia." Haematologica, the Hematology Journal 98, no. 5 (2013).
MLA-Zitierstil (9. Ausg.)Lange, Thoralf, und Martin Christian Müller. "The Quantitative Level of T315I Mutated BCR-ABL Predicts for Major Molecular Response to Second-line Nilotinib or Dasatinib Treatment in Patients with Chronic Myeloid Leukemia." Haematologica, the Hematology Journal, vol. 98, no. 5, 2013.